For example, in lung cancer, miRNA panels derived from liquid biopsies can differentiate benign from malignant lesions (131), while in prostate cancer, lncRNAs such as PCA3 have been established as clinical diagnostic markers (132). Here, PCA3 is linked to prostate cancer.